Reduced Lymphatic Function Predisposes to Calcium Channel Blocker Edema: A Randomized Placebo-Controlled Clinical Trial
Related Experiment Video
Updated: Jan 20, 2026
Author Spotlight: Advancements and Challenges in Surgical Treatments for Postamputation Pain
Published on: March 8, 2024
Sheyanth Mohanakumar1,2, Niklas Telinius1,2, Benjamin Kelly1,2
1Department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital, Aarhus N, Denmark.
Insights
Calcium channel blockers (CCBs) do not directly impair lymphatic function. However, individuals with pre-existing reduced lymphatic function may be more prone to developing CCB-induced edema.
Area of Science:
- Cardiovascular Physiology
- Lymphatic System Dynamics
- Pharmacology
Background:
- Calcium channel blockers (CCBs) are commonly prescribed antihypertensive medications.
- CCB-induced edema is a frequent side effect, often attributed to altered fluid dynamics in blood vessels.
- The role of lymphatic function in CCB-induced edema has not been thoroughly investigated.
Purpose of the Study:
- To investigate the direct impact of a CCB (amlodipine) on lymphatic vessel function.
- To determine if impaired lymphatic function is a predisposing factor for CCB-induced edema.
Main Methods:
- A 12-week double-blinded, randomized, placebo-controlled crossover trial involving 16 healthy postmenopausal women.
- Assessment of lymphatic function using near-infrared fluorescence imaging, measuring parameters like pumping pressure, contraction frequency, refill time, and lymph packet velocity.
- Comparison of lymphatic function during amlodipine treatment versus placebo, and analysis of baseline lymphatic function in subjects who developed edema versus those who did not.
Main Results:
- Amlodipine treatment did not significantly alter lymphatic pumping pressure, contraction frequency, refill time, or lymph packet velocity compared to placebo.
- Subjects who developed edema during CCB treatment exhibited a significantly lower baseline lymphatic pumping pressure (20% reduction) compared to those unaffected by edema.
- No significant differences in baseline contraction frequency, refill time, or lymph packet velocity were observed between the edema and non-edema groups.
Conclusions:
- CCB treatment, specifically with amlodipine, does not appear to directly impair lymphatic vessel function.
- Reduced baseline lymphatic function, particularly lower pumping pressure, may predispose individuals to developing edema when treated with CCBs.
- These findings suggest a potential mechanism for CCB-induced edema related to an individual's inherent lymphatic capacity.
Abstract:
The current belief is that the calcium channel blocker (CCB)-induced edema is due to a preferential arterial over venous dilatation leading to increased fluid filtration. We challenged this conviction by measuring the lymphatic removal of interstitial fluid during chronic systemic treatment with the CCB, amlodipine. Lymphatic vessels could potentially be an off-target effect of the drugs and play a role in CCB edema. Sixteen healthy postmenopausal women completed a 12-week double-blinded randomized placebo-controlled crossover trial. Lymphatic function was assessed by near-infrared fluorescence imaging. The lymphatic function during amlodipine treatment compared with placebo did not show any difference in pumping pressure (53.9 ± 13.9 mmHg vs. 54.7 ± 9.4 mmHg, p = 0.829), contraction frequency (0.4 ± 0.2/min vs. 0.4 ± 0.3/min, p = 0.932), refill time (440 ± 438 seconds vs. 442 ± 419 seconds, p = 0.990), or propagation velocity of lymph packets (18 ± 10 mm/s vs. 15 ± 7 mm/s, p = 0.124). However, the subjects who developed edema during CCB treatment had a 20% lower baseline lymphatic pumping pressure (48.9 ± 4.4 mmHg, n = 7) than the subjects not affected by treatment (59.1 ± 1.2 mmHg, n = 9, p = 0.025). Contraction frequency, refill time, and lymph packet velocity showed no differences in baseline values between the two groups. Our results suggest that CCB does not directly impair lymphatic function. However, our results show that a reduced lymphatic function predisposes to CCB edema, which may explain why some patients develop edema during treatment.
Related Concept Videos
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:54The Placebo Effect
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...